Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

The British government last month announced a £279 million ($365 million) investment by American multinational Eli Lilly that ...

Currently, Hims & Hers can offer compounded semaglutide due to the patent-related supply shortages affecting patent holders ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two ...

The Mounjaro manufacturer, Eli Lilly, said patient safety was the company’s top priority ... Due to the soaring demand for ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

One shipment of suspected counterfeit Wegovy was hidden inside a Mickey Mouse puzzle for ... FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...